IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF
Innate Pharma SA
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026
$1.46+0.03 (+2.10%)
Close on Oct 19, 2026
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Sep 17, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 26, 2026 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Sep 17, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 27, 2025 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Sep 12, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 21, 2024 | Before market open | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Sep 14, 2023 | Before market open | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 23, 2023 | Before market open | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Sep 15, 2022 | Before market open | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Mar 24, 2022 | Before market open | – | – | – |
Press releases
Announcements Innate Pharma filed with the SEC
INNATE PHARMA REPORTS FIRST HALF 2026 BUSINESS UPDATE AND FINANCIAL RESULTS
EX-99.1 to Form 6-K
French société anonyme governed by a Board of Directors
EX-99.2 to Form 6-K
for New Ordinary Shares of
EX-99.1 to Form 6-K
Innate Pharma announces conference call and webcast
EX-99.1 to Form 6-K
Outcome of Innate Pharma’s 2026 Annual General Meeting
EX-99.1 to Form 6-K
Innate Pharma to participate in the Jefferies Global Healthcare Conference
EX-99.1 to Form 6-K
Number of shares and voting rights of Innate Pharma as of April 16, 2026
EX-99.1 to Form 6-K
Innate Pharma to participate in the D. Boral Capital Global Conference
EX-99.1 to Form 6-K
INNATE PHARMA TO PRESENT MATISSE PHASE 2 INTERIM RESULTS
EX-99.1 to Form 6-K
Number of shares and voting rights of Innate Pharma as of April 9, 2026
EX-99.1 to Form 6-K
INNATE PHARMA TO PRESENT AT THE AACR 2026 ONCOLOGY INDUSTRY PARTNERING EVENT
EX-99.1 to Form 6-K
Innate Pharma to participate in the Kempen Life Sciences conference
EX-99.1 to Form 6-K
INNATE PHARMA REPORTS FULL YEAR 2025 FINANCIAL RESULTS AND BUSINESS UPDATE
EX-99.1 to Form 6-K
NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF DECEMBER 31, 2025
EX-99.1 to Form 6-K
NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF DECEMBER 18, 2025
EX-99.1 to Form 6-K
INNATE PHARMA RELEASES ITS 2026 FINANCIAL CALENDAR
EX-99.1 to Form 6-K
NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF NOVEMBER 27, 2025
EX-99.1 to Form 6-K
INNATE PHARMA TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
EX-99.1 to Form 6-K
INNATE PHARMA REPORTS FIRST HALF 2025 BUSINESS UPDATE AND FINANCIAL RESULTS
EX-99.1 to Form 6-K
French société anonyme governed by a Board of Directors
EX-99.2 to Form 6-K